James Mutamba

ImYoo is debugging the human immune system. By coupling at-home blood collection and single-cell RNA sequencing, we enable high resolution insights across time.

Redona Therapeutics is focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease.

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).

A London-based biotechnology company focussed on the discovery and development of inhaled anti-infective medicines for the treatment of fungal and viral infections of the lung.

ImYoo is debugging the human immune system. By coupling at-home blood collection and single-cell RNA sequencing, we enable high resolution insights across time.

Redona Therapeutics is focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease.

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).

We’re Colorescience, and we know healthy skin. From sunlight, to pollution, to free radicals, we believe in going way beyond UV. We’re obsessively overprotective about preventing skin damage. And that’s exactly why physicians love us. We know skincare innovation. We believe skincare battles are best won before they are fought. Because investing in scientific innovation now, means we won’t have to pay the price for free radicals later. We know sun protection. When it comes to sunscreen, we believe it should be a purely physical relationship—not a chemical one. Because the best defense is a mineral suncare offense.

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems.